Rifaximin for the treatment of hepatic encephalopathy.
Hepatic encephalopathy (HE) is a complication of cirrhosis, the severity of which can range from subtle, neurocognitive dysfunction (minimal HE) to more apparent and severe cognitive and motor manifestations with increasing grades of the condition (overt HE). Current treatment options are targeted at reducing the levels of ammonia and other gut-derived toxins, the purported culprits behind the pathogenesis of HE. One of these therapeutic options, the nonsystemic antibiotic rifaximin, is efficacious for the treatment of minimal and overt HE. However, HE may be a cyclic condition in which patients with overt HE enter remission following treatment and then relapse. Thus, safe, effective and well-tolerated treatments are needed to maintain HE remission. Rifaximin maintained HE remission more effectively than placebo in a large, randomized controlled trial. Rifaximin is safe and well-tolerated for the treatment of minimal and overt HE and for the maintenance of HE remission.
Division of Gastroenterology, MetroHealth Medical Center, Case Western Reserve University, 2500 MetroHealth Drive, Cleveland, OH 44109, USA.
Kevin
K
Mullen
Ravi
R
Prakash
D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006501:Hepatic Encephalopathy / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D006801:Humans; D015994:Incidence; D015995:Prevalence; D012074:Remission Induction; D012294:Rifamycins / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D000078262:Rifaximin; D016896:Treatment Outcome
D005765:Gastrointestinal Agents; D012294:Rifamycins; D000078262:Rifaximin